Dupixent® (Dupilumab) 关键试验达成所有主要和次要终点,减轻过敏性真菌性鼻窦炎(Afrs)的症状;Sbla获FDA优先审查

美股速递
Nov 07, 2025

Dupixent® (Dupilumab) 关键试验达成所有主要和次要终点,减轻过敏性真菌性鼻窦炎(Afrs)的症状;Sbla获FDA优先审查。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10